[Five cases of myelodysplastic syndrome treated with cytarabine ocfosfate].

Abstract

Five cases of myelodysplastic syndrome were treated with cytarabine ocfosfate. Ocfosfate (100-200 mg) was orally administered for 14 days with 14 days' interval. Etoposide was combined in one case, and nartograstim was added in two cases. Two of the five cases achieved remission, one case having complete remission, and another case showing a good response. Their remission durations were 141 and 112 days, respectively. Further improvement of therapy is needed to achieve a higher remission rate and a longer remission duration.

• Authors: T Nishi, M Funasako, N Hata, K Andoh, Y Itoh, H Ono, K Itoh, Y Sato, H Sato, M Taniji, S Nakai, A Ueda, H Fujimoto, M Ohata
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 23 Issue 10 Pg. 1331-4 (Sep 1996) ISSN: 0385-0684 [Print] Japan
• PMID: 8831748 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• Arabinonucleotides
• Granulocyte Colony-Stimulating Factor
• 1-arabinofuranosylcytosine-5'-stearylphosphate
• Etoposide
• Cytidine Monophosphate
• nartograstim

Topics

• Administration, Oral
• Antineoplastic Agents (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Arabinonucleotides (administration & dosage)
• Cytidine Monophosphate (administration & dosage, analogs & derivatives)
• Etoposide (administration & dosage)
• Female
• Granulocyte Colony-Stimulating Factor (administration & dosage)
• Humans
• Male
• Middle Aged
• Myelodysplastic Syndromes (drug therapy)
• Remission Induction